James Irwin, MD
Clinical Cardiac Electrophysiology · Lutz, FLNPI 1669418901
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (38.7%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Medtronic at 33.1% of the total. Reporting peaked in 2019 at $7,484 and has fallen 86.1% since, to $1,040 in 2025. That places this record below the midpoint for clinical cardiac electrophysiology clinicians in FL, where the typical reported total is $25,729.
Across 251 payments — averaging $69.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$6K
- Abbott$5K
- Boston Scientific$4K
- Novartis$296
- Biosig Technologies, Inc.$248
- Biotronik Inc.$200
- plus $1K from 20 others
Across 79 payments — averaging $6292.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$442K
- Abbott$55K
What the payments were for
- Consulting fees$3,67521%
- Speaking & faculty fees$3,75021%
- Travel & lodging$3,25319%
- Food & beverage$6,75939%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 69 | $5,771 |
| Abbott | 56 | $5,466 |
| Boston Scientific | 34 | $4,361 |
| Novartis | 18 | $296 |
| Biosig Technologies, Inc. | 1 | $248 |
| Biotronik Inc. | 6 | $200 |
| Sanofi-aventis U.S. LLC | 15 | $199 |
| Pfizer | 8 | $148 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $138 |
| E.r. Squibb & Sons, L.L.C. | 6 | $98 |
| Cardiva Medical, Inc. | 2 | $71 |
| Kestra Medical Technology Services, Inc. | 2 | $58 |
| Amgen | 3 | $54 |
| Johnson & Johnson | 4 | $53 |
| Novo Nordisk | 3 | $53 |
| Boehringer Ingelheim | 2 | $41 |
| Portola Pharmaceuticals, LLC | 2 | $38 |
| Siemens Medical Solutions USA, Inc. | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $19 |
| Penumbra, Inc. | 2 | $17 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
| AstraZeneca | 1 | $17 |
| Smith+Nephew | 1 | $16 |
| Scpharmaceuticals Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ensite Cardiac Mapping System$3,950
- Rhythmia Mapping System$3,750
- COBALT DR MRI SURESCAN$317
- PURE EP SYSTEM$248
- Watchman$246
- EVERA MRI XT DR SURESCAN$209
- ENSITE$181
- OMNIASECURE MRI SURESCAN$176
- ARCTIC FRONT ADVANCE$174
- Micra$165
- AMPLATZER AMULET$163
- ENSITE PRECISION$150
- AMPLATZER$144
- AVEIR$142
- Adapta$125
- Confirm Rx$109
How this compares
$17,450 in reported general payments places this provider in the 35th percentile of 249 clinical cardiac electrophysiology providers in Florida.
See all clinical cardiac electrophysiology providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 200 | $174,221 |
| XareltoRivaroxaban | 42 | $47,563 |
| Dofetilide | 104 | $16,811 |
| EntrestoSacubitril/Valsartan | 12 | $10,063 |
| Repatha SureclickEvolocumab | 11 | $6,149 |
| Flecainide Acetate | 24 | $1,247 |
| Metoprolol Succinate | 102 | $989 |
| Ezetimibe | 32 | $813 |
| Midodrine Hcl | 16 | $669 |
| Irbesartan | 47 | $461 |
| Amiodarone Hcl | 26 | $441 |
| Rosuvastatin Calcium | 36 | $304 |
| Carvedilol | 34 | $240 |
| Losartan Potassium | 24 | $227 |
| Spironolactone | 12 | $221 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $148 | $174,221200 claims |
| Johnson & JohnsonXarelto | $53 | $47,56342 claims |
| NovartisEntresto | $296 | $10,06312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 249 clinical cardiac electrophysiology providers in Florida.
Other clinical cardiac electrophysiology in Lutz
- Usman SiddiquiWinter Park$1.2M
- Jose Osorio FilhoMiami$1.2M
- David KenigsbergFort Lauderdale$1M
- Raul WeissMiami Beach$887K
- Naushad ShaikKissimmee$691K
- Parikshit SharmaWeston$462K
- Saumil OzaJacksonville$462K
- Brian BetenskySarasota$412K
- Antonio MorettaSarasota$312K
- Marcelo JimenezAtlantis$295K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.